Workflow
L102
icon
Search documents
管线覆盖ADC和RLT,这家创新药企总融资近6亿美元
3 6 Ke· 2025-06-22 01:59
2025年1月,Immunome完成1.5亿美元融资,此轮融资将推动核心管线的临床转化。3月,Immunome宣布靶向ROR1的ADC(抗体-偶联药物)IM-1021完 成I期临床试验首例患者给药。其核心产品管线Varegacestat(AL102)Ⅲ期RINGSIDE试验也已完成入组,预计2025年下半年公布顶线数据。 Immunome的核心竞争力是快速抗体筛选与精准递送技术。高效、精准且安全性高的治疗优势突破了传统癌症治疗中"脱靶损伤"与研发周期过长的行业瓶 颈。 这家临床阶段的靶向肿瘤学公司已累计融资5.989亿美元、21轮资本加持——成立17年的Immunome,凭什么让投资者持续买单? 利用天然抗体解决脱靶损伤的精准性难题 传统化疗与放疗的局限性在于其作用机制缺乏特异性,药物或辐射在攻击癌细胞的同时会无差别损伤快速分裂的健康细胞(如骨髓、消化道细胞),导致 患者免疫力下降、脱发等严重副作用。这种攻击对人体健康组织损伤率高达60%。以胰腺癌为例,传统放疗虽能缩小肿瘤,但患者容易出现消化道溃疡等 严重并发症。 据塔夫茨药物开发研究中心数据,开发一款新药平均耗时10年、耗资26亿美元左右,且90%以上候选 ...
来凯医药20250616
2025-06-16 15:20
来凯医药 20250616 来凯医药将在本月 20 号召开的美国 ADA 大会上展示两份重要内容。首先是 L102 针对肥胖症的临床一期 SAD 详细数据报告。其次是 L1,102,103 和 123 的临床前动物实验探索,特别是 AKT1 和 AKT2 两个不同靶点作用机制的数据 验证。这些数据将首次发表,展示来凯医药在信号通道上的全球领先探索。 来凯医药在减肥药市场上的研发策略是什么? 来凯医药在减肥药市场上致力于开发高质量的减脂不减肌方案。公司依托创业 团队 30 多年的深耕,目前全球唯一一家对 ICAR-2 信号传导路径中的 a 和 b 两 个受体进行单独靶点抑制,拥有 ICAR-TWO-A、ICAR-TWO-B 以及 ICAR- TWO-AB 三款抗体,实现全方位布局。在此次 ADA 大会上,公司将汇报去年 AKT 抑制剂 L1,002 是全球第二款、国内首款,正进行新药申请,临床 数据与阿斯利康 Capivasertib 类似,但安全性更佳,预计国内 HER2 阳性乳腺癌适应症销售峰值可达十几至二十亿人民币。 礼来收购 Gubra 表明其重视增肌方向,并积极布局该领域。礼来将在 6 月 23 日公 ...
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
ZACKS· 2025-05-09 15:45
Financial Performance - Rocket Pharmaceuticals incurred a loss of 56 cents per share in Q1 2025, which is narrower than the Zacks Consensus Estimate of a loss of 59 cents and an improvement from a loss of 66 cents per share in the same quarter last year [1] - The company did not record any revenues in the reported quarter, missing the Zacks Consensus Estimate for total revenues of $8 million [2] - General and administrative expenses rose 28% year over year to $28.4 million, attributed to increased commercial preparation and legal expenses [2] - Research and development expenses were $35.9 million, down 21% from the previous year due to reduced manufacturing and development costs [3] - As of March 31, 2025, the company had cash, cash equivalents, and investments totaling $318.2 million, down from $372.3 million as of December 31, 2024, with expectations to fund operations into Q4 2026 [3] - Year to date, RCKT shares have declined 44%, compared to an 8% decline in the industry [4] Pipeline Developments - Kresladi, developed for treating severe leukocyte adhesion deficiency-I (LAD-I), received a complete response letter (CRL) from the FDA in June 2024, requesting limited additional information on the Chemistry Manufacturing and Controls (CMC) [7][8] - The company plans to file a complete BLA to resolve the CRL later in 2025 [8] - Rocket Pharmaceuticals is developing RP-L102 for treating Fanconi anemia (FA) and has initiated a rolling BLA, expecting to complete the submission in late 2025 or early 2026 [9] - Dosing is currently underway in a phase II pivotal study for RP-A501, targeting male patients with Danon disease, with clinical data readout expected in mid-2026 [10]